Sacituzumab Govitecan in patients with breast cancer brain metastases and recurrent glioblastoma: a phase 0 window-of-opportunity trial

Abstract Sacituzumab Govitecan (SG) is an antibody-drug conjugate that has demonstrated efficacy in patients with TROP-2 expressing epithelial cancers. In a xenograft model of intracranial breast cancer, SG inhibited tumor growth and increased mouse survival. We conducted a prospective window-of-opp...

Full description

Bibliographic Details
Published in:	Nature Communications
Main Authors:	Henriette U. Balinda, William J. Kelly, Virginia G. Kaklamani, Kate I. Lathrop, Marcela Mazo Canola, Pegah Ghamasaee, Gangadhara R. Sareddy, Joel Michalek, Andrea R. Gilbert, Prathibha Surapaneni, Stefano Tiziani, Renu Pandey, Jennifer Chiou, Alessia Lodi, John R. Floyd, Andrew J. Brenner
Format:	Article
Language:	English
Published:	Nature Portfolio 2024-08-01
Online Access:	https://doi.org/10.1038/s41467-024-50558-9

Similar Items

Distinct effects of sacituzumab govitecan and berzosertib on DNA damage response in ovarian cancer
by: Jayakumar R. Nair, et al.
Published: (2024-12-01)

Sacituzumab-govitecan-induced severe acute tubulointerstitial nephritis requiring hemodialysis
by: Geneva Guarin, et al.
Published: (2024-11-01)

Sacituzumab govitecan expands its therapeutic spectrum among breast cancer subtypes
by: Semir Vranic
Published: (2023-03-01)

Sacituzumab govitecan in triple-negative breast cancer: from bench to bedside, and back
by: Valentina Rossi, et al.
Published: (2024-08-01)

Efficacy and safety of Sacituzumab govitecan in solid tumors: a systematic review and meta-analysis
by: Yaping Zhang, et al.
Published: (2025-06-01)

Sacituzumab govitecan in heavily pretreated, platinum-resistant high grade serous ovarian cancer
by: Michelle Greenman, et al.
Published: (2024-08-01)

A rare case of advanced metaplastic breast carcinoma with response to treatment with Sacituzumab govitecan
by: Sharlene Dong, et al.
Published: (2023-06-01)

Safety profile of sacituzumab govitecan in patients with breast cancer: A systematic review and meta-analysis
by: Maria Inez Dacoregio, et al.
Published: (2025-02-01)

Post-marketing safety surveillance of sacituzumab govitecan: an observational, pharmacovigilance study leveraging FAERS database
by: Wensheng Liu, et al.
Published: (2023-11-01)

A New Kid on the Block: Sacituzumab Govitecan for the Treatment of Breast Cancer and Other Solid Tumors
by: Giuliana Pavone, et al.
Published: (2021-12-01)

Cost-effectiveness of sacituzumab govitecan versus chemotherapy in advanced or metastatic triple-negative breast cancer
by: Yitian Lang, et al.
Published: (2023-04-01)

Real-World outcomes with sacituzumab govitecan among breast cancer patients with central nervous system metastases
by: Thomas Grinda, et al.
Published: (2025-03-01)

Targeting Refractory Triple-Negative Breast Cancer with Sacituzumab Govitecan: A New Era in Precision Medicine
by: Saif Khan, et al.
Published: (2024-12-01)

Subgroup analyses from the phase 3 ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer
by: Sara A. Hurvitz, et al.
Published: (2024-04-01)

Sacituzumab govitecan response in extensive leptomeningeal carcinomatosis from triple-negative breast cancer: a case report
by: Jesús Yaringaño, et al.
Published: (2024-08-01)

Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer
by: Hope S. Rugo, et al.
Published: (2022-08-01)

Cost-effectiveness of sacituzumab govitecan versus chemotherapy in patients with relapsed or refractory metastatic triple-negative breast cancer
by: Jiao Xie, et al.
Published: (2023-06-01)

Sacituzumab govitecan as second-line treatment for metastatic triple-negative breast cancer—phase 3 ASCENT study subanalysis
by: Lisa A. Carey, et al.
Published: (2022-06-01)

UGT1A1*28 polymorphism and the risk of toxicity and disease progression in patients with breast cancer receiving sacituzumab govitecan
by: Megan H. Wong, et al.
Published: (2024-08-01)

SAGA—a phase Ib/II single-arm, multicenter study of sacituzumab govitecan for patients with metastatic esophagogastric adenocarcinoma
by: B. Kobitzsch, et al.
Published: (2024-06-01)

Sacituzumab Govitecan for the treatment of advanced triple negative breast cancer patients: a multi-center real-world analysis
by: Roberta Caputo, et al.
Published: (2024-03-01)

Response to trastuzumab deruxtecan in a patient with HER2-low metastatic breast cancer previously treated with sacituzumab govitecan
by: Stefano Testa, et al.
Published: (2023-09-01)

Exceptional response to TROP2 inhibition with sacituzumab govitecan in a patient with small cell carcinoma of the breast: a case report
by: Kasey C. Fitzsimmons, et al.
Published: (2025-02-01)

Author Correction: Subgroup analyses from the phase 3 ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer
by: Sara A. Hurvitz, et al.
Published: (2024-07-01)

Author Correction: Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer
by: Hope S. Rugo, et al.
Published: (2024-06-01)

Comparison of trastuzumab deruxtecan and sacituzumab govitecan in HER2-negative metastatic breast cancer: a large real-world data analysis
by: George W. Jr. Sledge, et al.
Published: (2025-08-01)

Q-TWiST Analysis of Sacituzumab Govitecan vs. Chemotherapy in Previously Treated Patients with HR+/HER2− Metastatic Breast Cancer
by: Hope S. Rugo, et al.
Published: (2025-03-01)

Real-world safety and effectiveness data of trastuzumab deruxtecan and sacituzumab govitecan in breast cancer: a Hellenic Cooperative Oncology Group study
by: E. Fountzilas, et al.
Published: (2025-03-01)

Canadian Expert Recommendations on Safety Overview and Toxicity Management Strategies for Sacituzumab Govitecan Based on Use in Metastatic Triple-Negative Breast Cancer
by: Mita Manna, et al.
Published: (2024-09-01)

662 Phase I/II study of ipilimumab plus nivolumab combined with sacituzumab govitecan in patients with metastatic cisplatin-ineligible urothelial carcinoma
by: Rohit Jain, et al.
Published: (2023-11-01)

Preclinical evidence for the use of anti‐Trop‐2 antibody‐drug conjugate Sacituzumab govitecan in cerebral metastasized castration‐resistant prostate cancer
by: Richard Weiten, et al.
Published: (2024-06-01)

Cost-effectiveness of sacituzumab govitecan versus single-agent chemotherapy for metastatic triple-negative breast cancer: a trial-based analysis
by: Yilai Wu, et al.
Published: (2024-04-01)

Cost-effectiveness of sacituzumab govitecan in hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer
by: Demin Shi, et al.
Published: (2023-05-01)

Effectiveness and Safety of Sacituzumab Govitecan in Real-World Clinical Practice in Patients with Metastatic Triple-Negative and HR+/HER2-Negative Breast Cancer
by: Fernando Lago-Ballester, et al.
Published: (2025-08-01)

Assessing real-world safety concerns of Sacituzumab govitecan: a disproportionality analysis using spontaneous reports in the FDA adverse event reporting system
by: Xiujuan Gui, et al.
Published: (2023-10-01)

TROPHIT1—a randomized, open-label, multicenter, phase II/III trial of sacituzumab govitecan compared to standard of care in metastatic colorectal cancer patients
by: B.C. Köhler, et al.
Published: (2025-03-01)

Comparative pharmacological analysis of fam-trastuzumab deruxtecan-nxki and sacituzumab govitecan-hziy: Two recently developed chemotherapies in the crucial battle against breast cancer
by: Amjad Z. Alrosan, et al.
Published: (2025-06-01)

MMP1-induced NF-κB activation promotes epithelial–mesenchymal transition and sacituzumab govitecan resistance in hormone receptor-positive breast cancer
by: Letian Chen, et al.
Published: (2025-04-01)

Sacituzumab Govitecan for Second and Subsequent Line Palliative Treatment of Patients with Triple-Negative Breast Cancer: A Polish Real-World Multicenter Cohort Study
by: Miroslawa Püsküllüoğlu, et al.
Published: (2024-09-01)

Safety and effectiveness of sacituzumab govitecan in patients with metastatic triple-negative breast cancer in real-world settings: first observations from an interdisciplinary breast cancer centre in Germany
by: Mattea Reinisch, et al.
Published: (2023-09-01)